Bristol's New Chief Scientific Officer Lists Oncology Priorities, But Little New

 
• By Lucie Ellis-Taitt

At ASCO, Bristol-Myers-Squibb's new Chief Scientific Officer Thomas Lynch highlighted key R&D priorities for advancing the company's cancer pipeline and staying ahead of its competitors.

BMY Chief Scientific Officer Thomas Lynch
BMS chief scientific officer Thomas Lynch reels off list of R&D priorities on ASCO call

More from Strategy

More from Business